Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options

References

• KirkpatrickBGalderisiSDeficit schizophrenia: an updateWorld Psychiatry20087314314718836581
   PubMed Web of Science ®Google Scholar
• AndreasenNCNegative symptoms in schizophrenia. Definition and reliabilityArch Gen Psychiatry19823977847887165477
   PubMed Web of Science ®Google Scholar
• BlanchardJJKringAMHoranWPGurRToward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophreniaSchizophr Bull201137229129920861151
   PubMed Web of Science ®Google Scholar
• FoussiasGRemingtonGNegative symptoms in schizophrenia: avolition and Occam’s razorSchizophr Bull201036235936918644851
   PubMed Web of Science ®Google Scholar
• ChoiJMedaliaAIntrinsic motivation and learning in a schizophrenia spectrum sampleSchizophr Res20101181–3121919716270
   PubMed Web of Science ®Google Scholar
• TammingaCABuchananRWGoldJMThe role of negative symptoms and cognitive dysfunction in schizophrenia outcomeInt Clin Psychopharmacol199813Suppl 3S21S269690966
   PubMed Web of Science ®Google Scholar
• PeraltaVCuestaMJMartinez-LarreaASerranoJFDifferentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatmentAm J Psychiatry200015791461146610964863
   PubMed Web of Science ®Google Scholar
• HovingtonCLBodnarMJooberRMallaAKLepageMIdentifying persistent negative symptoms in first episode psychosisBMC Psychiatry20121222423217020
   PubMed Web of Science ®Google Scholar
• ChangWCHuiCLTangJYPersistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up studySchizophr Res20111331–3222821968080
   PubMed Web of Science ®Google Scholar
• MäkinenJMiettunenJJääskeläinenEVeijolaJIsohanniMKoponenHNegative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth CohortPsychiatr Res20101781121125
   Web of Science ®Google Scholar
• GalderisiSBucciPÜçokAPeuskensJNo gender differences in social outcome in patients suffering from schizophreniaEur Psychiatry201227640640821616645
   PubMed Web of Science ®Google Scholar
• BobesJArangoCGarcia-GarciaMRejasJCLAMORS Study Collaborative GroupPrevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS studyJ Clin Psychiatry201071328028619895779
   PubMed Web of Science ®Google Scholar
• TekCKirkpatrickBBuchananRWA five-year followup study of deficit and nondeficit schizophreniaSchizophr Res200149325326011356586
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBAmerican Psychiatric Association, Steering Committee on Practice GuidelinesPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry2004161suppl 215615000267
   PubMed Web of Science ®Google Scholar
• FlaumMAndreasenNThe reliability of distinguishing primary versus secondary negative symptomsCompr Psychiatry19953664214278565446
   PubMed Web of Science ®Google Scholar
• PeraltaVCuestaMJNegative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisitedSchizophr Res199940324525310638863
   PubMed Web of Science ®Google Scholar
• BuchananRWJavittDCMarderSRThe cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairmentsAm J Psychiatry2007164101593160217898352
   PubMed Web of Science ®Google Scholar
• MäkinenJMiettunenJIsohanniMKoponenHNegative symptoms in schizophrenia: a reviewNord J Psychiatry200862533434118752104
   PubMed Web of Science ®Google Scholar
• GalderisiSBucciPMucciACategorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcomeSchizophr Res2013147115716223608244
   PubMed Web of Science ®Google Scholar
• FervahaGFoussiasGAgidORemingtonGAmotivation and functional outcomes in early schizophreniaPsychiatry Res2013210266566823911005
   PubMed Web of Science ®Google Scholar
• FoussiasGNegative symptoms across the schizophrenia spectrum: Phenomenological and neurobiological perspectivesRitsnerMSHandbook of Schizophrenia Spectrum Disorders, Volume II: Phenotypic and Endophenotypic PresentationsNew York, NYSpringer2011132
   Google Scholar
• DowdECBarchDMAnhedonia and emotional experience in schizophrenia: neural and behavioral indicatorsBiol Psychiatry2010671090291120004364
   PubMed Web of Science ®Google Scholar
• GoldJMWaltzJAPrenticeKJMorrisSEHeereyEAReward processing in schizophrenia: a deficit in the representation of valueSchizophr Bull200834583584718591195
   PubMed Web of Science ®Google Scholar
• GoghariVMSponheimSRMacDonaldAW3rdThe functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent questionNeurosci Biobehav Rev201034346848619772872
   PubMed Web of Science ®Google Scholar
• HarveyPOArmonyJMallaALepageMFunctional neural substrates of self-reported physical anhedonia in non-clinical individuals and in patients with schizophreniaJ Psychiatr Res2010441170771620116072
   PubMed Web of Science ®Google Scholar
• JuckelGSchlagenhaufFKoslowskiMDysfunction of ventral striatal reward prediction in schizophreniaNeuroimage200629240941616139525
   PubMed Web of Science ®Google Scholar
• LewisDAMoghaddamBCognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterationsArch Neurol200663101372137617030651
   PubMedGoogle Scholar
• MuraseSMathéJMGrenhoffJSvenssonTHEffects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localizationJ Neural Transm Gen Sect199391113258452684
   PubMed Web of Science ®Google Scholar
• WitkinJMBlockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonistsLife Sci19935324PL405PL4107902523
   PubMed Web of Science ®Google Scholar
• TakahataRMoghaddamBGlutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortexJ Neurochem1998714144314499751176
   PubMed Web of Science ®Google Scholar
• KissTHoffmannWEScottLRole of thalamic projection in NMDA receptor-induced disruption of cortical slow oscillation and short-term plasticityFront Psychiatry201121421556284
   PubMedGoogle Scholar
• TomitakaSTomitakaMTolliverBKSharpFRBilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortexEur J Neurosci20001241420143010762370
   PubMed Web of Science ®Google Scholar
• LorrainDSBacceiCSBristowLJAndersonJJVarneyMAEffects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268Neuroscience2003117369770612617973
   PubMed Web of Science ®Google Scholar
• KirkpatrickBFentonWSCarpenterWTJrMarderSRThe NIMH-MATRICS consensus statement on negative symptomsSchizophr Bull200632221421916481659
   PubMed Web of Science ®Google Scholar
• KringAMGurREBlanchardJJHoranWPReiseSPThe Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validationAm J Psychiatry2013170216517223377637
   PubMed Web of Science ®Google Scholar
• StraussGPKellerWRBuchananRWNext-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom ScaleSchizophr Res2012a1421–3889223127378
   PubMed Web of Science ®Google Scholar
• MarderSRDavisJMChouinardGThe effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trialsJ Clin Psychiatry199758125385469448657
   PubMed Web of Science ®Google Scholar
• LevineSZRabinowitzJRevisiting the 5 dimensions of the Positive and Negative Syndrome ScaleJ Clin Psychopharmacol200727543143617873671
   PubMed Web of Science ®Google Scholar
• MarderSRKirkpatrickBDefining and measuring negative symptoms of schizophrenia in clinical trialsEur Neuropsychopharmacol2013 Epub111110.1016/j.euroneuro.2013.10.016
   Web of Science ®Google Scholar
• MarderSRDanielDGAlphsLAwadGMethodological issues in negative symptom trialsSchizophr Bull201137225025421270473
   PubMed Web of Science ®Google Scholar
• MarderSRAlphsLAnghelescuIIssues and perspectives in designing clinical trials for negative symptoms in schizophreniaSchizophr Res20131502–332833324028744
   PubMed Web of Science ®Google Scholar
• HunterRBarrySNegative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatmentEur Psychiatry201227643243621602034
   PubMed Web of Science ®Google Scholar
• LlorcaPMBlancOSamalinLBosiaMCavallaroREGOFORS InitiativeFactors involved in the level of functioning of patients with schizophrenia according to latent variable modelingEur Psychiatry201227639640021723098
   PubMed Web of Science ®Google Scholar
• GreenMFWhat are the functional consequences of neurocognitive deficits in schizophrenia?Am J Psychiatry199615333213308610818
   PubMed Web of Science ®Google Scholar
• HoferABaumgartnerSEdlingerMPatient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effectsEur Psychiatry2005205–638639416171653
   PubMed Web of Science ®Google Scholar
• RosenheckRALeslieDLSindelarJCost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophreniaAm J Psychiatry2006163122080208917151158
   PubMed Web of Science ®Google Scholar
• RabinowitzJLevineSZGaribaldiGBugarski-KirolaDBerardoCGKapurSNegative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE dataSchizophr Res20121371–314715022316568
   PubMed Web of Science ®Google Scholar
• RabinowitzJBerardoCGBugarski-KirolaDMarderSAssociation of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysisSchizophr Res20131502–333934223899997
   PubMed Web of Science ®Google Scholar
• MilevPHoBCArndtSAndreasenNCPredictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-upAm J Psychiatry2005162349550615741466
   PubMed Web of Science ®Google Scholar
• FoussiasGMannSZakzanisKKvan ReekumRAgidORemingtonGPrediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficitsSchizophr Res20111321242721771567
   PubMed Web of Science ®Google Scholar
• LeifkerFRBowieCRHarveyPDDeterminants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptomsSchizophr Res20091151828719775869
   PubMed Web of Science ®Google Scholar
• KurtzMMOlfsonRHRoseJSelf-efficacy and functional status in schizophrenia: relationship to insight, cognition and negative symptomsSchizophr Res20131451–3697423375941
   PubMed Web of Science ®Google Scholar
• BouriciusJKNegative symptoms and emotions in schizophreniaSchizophr Bull19891522012082749183
   PubMed Web of Science ®Google Scholar
• BrekkeJSLevinSWolkonGHSobelESladeEPsychosocial functioning and subjective experience in schizophreniaSchizophr Bull19931935996088235461
   PubMed Web of Science ®Google Scholar
• EricksonMJaafariNLysakerPInsight and negative symptoms as predictors of functioning in a work setting in patients with schizophreniaPsychiatry Res2011189216116521813183
   PubMed Web of Science ®Google Scholar
• LysakerPBellMNegative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six monthsActa Psychiatr Scand19959132052087625197
   PubMed Web of Science ®Google Scholar
• WeinbergDShaharGDavidsonLMcGlashanTHFennigSLongitudinal associations between negative symptoms and social functioning in schizophrenia: the moderating role of employment status and settingPsychiatry200972437038120070135
   PubMed Web of Science ®Google Scholar
• StraussGPSandtARCatalanoLTAllenDNNegative symptoms and depression predict lower psychological well-being in individuals with schizophreniaCompr Psychiatry2012b5381137114422770716
   PubMed Web of Science ®Google Scholar
• LincolnTMMehlSKestingMLRiefWNegative symptoms and social cognition: identifying targets for psychological interventionsSchizophr Bull201137suppl 2S23S3221860044
   PubMed Web of Science ®Google Scholar
• FujimakiKMorinobuSYamashitaHTakahashiTYamawakiSPredictors of quality of life in inpatients with schizophreniaPsychiatry Res2012197319920522370148
   PubMed Web of Science ®Google Scholar
• StahlSMBuckleyPFNegative symptoms of schizophrenia: a problem that will not go awayActa Psychiatrica Scand20071151411
   Web of Science ®Google Scholar
• DyckDGShortRVitalianoPPPredictors of burden and infectious illness in schizophrenia caregiversPsychosom Med199961441141910443748
   PubMed Web of Science ®Google Scholar
• ProvencherHLMueserKTPositive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophreniaSchizophr Res199726171809376339
   PubMed Web of Science ®Google Scholar
• BrawYBenozioALevkovitzYExecutive functioning during full and partial remission (positive and negative symptomatic remission) of schizophreniaSchizophr Res20121421–312212823127380
   PubMed Web of Science ®Google Scholar
• NovickDHaroJMSuarezDVietaENaberDRecovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) studySchizophr Res20091081–322323019070991
   PubMed Web of Science ®Google Scholar
• LevineSZLeuchtSAttaining and sustaining remission of predominant negative symptomsSchizophr Res20131431606423218563
   PubMed Web of Science ®Google Scholar
• BarnesTRSchizophrenia Consensus Group of British Association for PsychopharmacologyEvidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for PsychopharmacologyJ Psychopharmacol201125556762021292923
   PubMed Web of Science ®Google Scholar
• SinghSPSinghVKarNChanKEfficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysisBr J Psychiatry2010197317417920807960
   PubMed Web of Science ®Google Scholar
• RummelCKisslingWLeuchtSAntidepressants for the negative symptoms of schizophreniaCochrane Database Syst Rev20063CD00558116856105
   PubMed Web of Science ®Google Scholar
• HechtEMLandyDCAlpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysisSchizophr Res20121342–320220622169246
   PubMed Web of Science ®Google Scholar
• BodkinJASirisSGBermanzohnPCHennenJColeJODouble-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophreniaAm J Psychiatry2005162238839015677608
   PubMed Web of Science ®Google Scholar
• AmiriANoorbalaAANejatisafaAAEfficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled studyHum Psychopharmacol2008232798617972359
   PubMed Web of Science ®Google Scholar
• StorosumJGElferinkAJvan ZwietenBJvan StrikRHoogendijkWJBroekmansAWAmisulpride: is there a treatment for negative symptoms in schizophrenia patients?Schizophr Bull200228219320112693427
   PubMed Web of Science ®Google Scholar
• LeuchtSKisslingWDavisJMSecond-generation antipsychotics for schizophrenia: can we resolve the conflict?Psychol Med2009391591160219335931
   PubMed Web of Science ®Google Scholar
• ArangoCGaribaldiGMarderSRPharmacological approaches to treating negative symptoms: A review of clinical trialsSchizophr Res20131502–334635223938176
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental HealthThe NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary CareUpdated EditionNational Clinical Guideline Number 82Leicester, UKThe British Psychological Society and The Royal College of Psychiatrists2010
   Google Scholar
• BuchananRWPanagidesJZhaoJAsenapine versus olanzapine in people with persistent negative symptoms of schizophreniaJ Clin Psychopharmacol2012321364522198451
   PubMed Web of Science ®Google Scholar
• PotkinSGPhiriPSzegediAZhaoJAlphsLCazorlaPLong-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: A pooled analysisSchizophr Res20131502–344244924075603
   PubMed Web of Science ®Google Scholar
• EssaliAAl-Haj HaasanNLiCRathboneJClozapine versus typical neuroleptic medication for schizophreniaCochrane Database Syst Rev20091CD00005919160174
   PubMed Web of Science ®Google Scholar
• UmbrichtDAlberatiDMartin-FacklamMEffect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept studyJAMA Psychiatry2014 Epub2410.1001/jamapsychiatry.2014.163
   Web of Science ®Google Scholar
• TsaiGELinPYStrategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysisCurr Pharm Des201016552253719909229
   PubMed Web of Science ®Google Scholar
• SinghSPSinghVMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaCNS Drugs2011251085988521936588
   PubMed Web of Science ®Google Scholar
• TsaiGLaneHYYangPChongMYLangeNGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophreniaBiol Psychiatry200455545245615023571
   PubMed Web of Science ®Google Scholar
• LaneHYChangYCLiuYCChiuCCTsaiGESarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled studyArch Gen Psychiatry200562111196120416275807
   PubMed Web of Science ®Google Scholar
• LaneHYHuangCLWuPLGlycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophreniaBiol Psychiatry200660664564916780811
   PubMed Web of Science ®Google Scholar
• LaneHYLiuYCHuangCLSarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind studyBiol Psychiatry200863191217659263
   PubMed Web of Science ®Google Scholar
• LaneHYLinCHHuangYJA randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaInt J Neuropsychopharmacol201013445146019887019
   PubMed Web of Science ®Google Scholar
• EvinsAEAmicoEPoseverTATokerRGoffDCD-Cycloserine added to risperidone in patients with primary negative symptoms of schizophreniaSchizophr Res2002561–2192312084415
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUJavittDCComparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysisSchizophr Res200466899615061240
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUJavittDCErmilovMDouble-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophreniaBr J Psychiatry19961696106178932891
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUJavittDCErmilovMEfficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophreniaArch Gen Psychiatry199956129369892253
   PubMed Web of Science ®Google Scholar
• JavittDCZylbermanIZukinSRHeresco-LevyULindenmayerJPAmelioration of negative symptoms in schizophrenia by glycineAm J Psychiatry19941518123412368037263
   PubMed Web of Science ®Google Scholar
• LaneHYLinCHGreenMFAdd-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitorJAMA Psychiatry201370121267127524089054
   PubMed Web of Science ®Google Scholar
• StaufferVLMillenBAAndersenSPomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placeboSchizophr Res20131502–343444124035403
   PubMed Web of Science ®Google Scholar
• De BoerPSinhaVHoebenECharacterization of the clinical effect of a positive allosteric modulator of the metabotropic glutamate receptor-2 [poster #998]Presented at 68th Annual Scientific Convention of Society of Biological PsychiatryMay 16–18, 2013San Francisco, CA
   Google Scholar
• EnVivo PharmaceuticalsEnVivo Pharmaceuticals presents positive comprehensive phase 2b study results in schizophrenia at American College of Neuropsychopharmacology annual meeting [press release]December 5, 2011 Available from: http://www.envivopharma.com/news-item.php?id=35Accessed March 5, 2014
   Google Scholar
• LiebermanJADunbarGSegretiACA randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophreniaNeuropsychopharmacology201338696897523303043
   PubMed Web of Science ®Google Scholar
• DeutschSISchwartzBLSchoolerNRBrownCHRosseRBRosseSMTargeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategySchizophr Res20131481–313814423768813
   PubMed Web of Science ®Google Scholar
• ChoiKHWykesTKurtzMMAdjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacyBr J Psychiatry201320317217823999481
   PubMed Web of Science ®Google Scholar
• Vyvanse (lisdexamfetamine dimesylate) [package insert]Wayne, PAShire US Inc.2013
   Google Scholar
• LasserRADirksBNasrallahHAdjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phasesNeuropsychopharmacology201338112140214923756608
   PubMed Web of Science ®Google Scholar
• LindenmayerJPNasrallahHPucciMJamesSCitromeLA systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunitiesSchizophr Res20131472–324125223619055
   PubMed Web of Science ®Google Scholar
• WittkampfLCArendsJTimmermanLLancelMA review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophreniaTher Adv Psychopharmacol20122311512523983964
   PubMedGoogle Scholar
• BerkMCopolovDDeanON-acetyl cysteine as a glutathione precursor for schizophrenia – a double-blind, randomized, placebo-controlled trialBiol Psychiatry200864536136818436195
   PubMed Web of Science ®Google Scholar
• ChaudhryIBHallakJHusainNMinocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatmentJ Psychopharmacol20122691185119322526685
   PubMed Web of Science ®Google Scholar
• LevkovitzYMendlovichSRiwkesSA double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophreniaJ Clin Psychiatry201071213814919895780
   PubMed Web of Science ®Google Scholar
• KishiTMukaiTMatsudaYIwataNSelective serotonin 3 receptor antagonist treatment for schizophrenia: Meta-analysis and systematic reviewNeuromolecular Med2014161616923896722
   PubMed Web of Science ®Google Scholar
• TiihonenJWahlbeckKKiviniemiVThe efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysisSchizophr Res20091091–3101419186030
   PubMed Web of Science ®Google Scholar
• KishiTIwataNNMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trialsJ Psychiatr Res20134791143114923692933
   PubMed Web of Science ®Google Scholar
• LiebermanJAPapadakisKCsernanskyJMEM-MD-29 Study GroupA randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophreniaNeuropsychopharmacology20093451322132919005465
   PubMed Web of Science ®Google Scholar
• MarxCEKeefeRSBuchananRWProof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaNeuropsychopharmacology20093481885190319339966
   PubMed Web of Science ®Google Scholar
• MarxCEBradfordDWHamerRMPregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidenceNeuroscience2011191789021756978
   PubMed Web of Science ®Google Scholar
• GoffDCCatherCFreudenreichOA placebo-controlled study of sildenafil effects on cognition in schizophreniaPsychopharmacology20092021–341141718716761
   PubMed Web of Science ®Google Scholar
• AkhondzadehSGhayyoumiRRezaeiFSildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trialPsychopharmacology2011213480981520949350
   PubMed Web of Science ®Google Scholar
• RoffmanJLLambertiJSAchtyesERandomized multicenter investigation of folate plus vitamin B12 supplementation in schizophreniaJAMA Psychiatry201370548148923467813
   PubMed Web of Science ®Google Scholar
• NunesEAMacKenzieEMRossolatosDPerez-ParadaJBakerGBDursunSMD-serine and schizophrenia: an updateExpert Rev Neurother201212780181222853788
   PubMed Web of Science ®Google Scholar
• ChuePBakerGBGlycine reuptake inhibition: a promising therapeutic strategy in the treatment of schizophrenia?Future Med Chem20135131475147724024940
   PubMed Web of Science ®Google Scholar
• ChuePGlycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)Curr Pharm Des20131971311132023194655
   PubMed Web of Science ®Google Scholar
• KantrowitzJTJavittDCN-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?Brain Res Bull20108310812120417696
   PubMed Web of Science ®Google Scholar
• Hoffmann-La RocheA Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated January 6, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01192906. NLM identifier: NCT01192906Accessed March 10, 2014
   Google Scholar
• Hoffmann-La RocheA Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25308)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated March 3, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01192880?term=NCT01192880&rank=1. NLM identifier: NCT01192880Accessed March 10, 2014
   Google Scholar
• Hoffmann-La RocheA Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated January 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01192867?term=NCT01192867&rank=1. NLM identifier: NCT01192867 Accessed March 10, 2104
   Google Scholar
• Hoffmann-La RocheA Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated March 3, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01235559?term=nCT01235559&rank=1. NLM identifier: NCT01235559Accessed March 3, 2014
   Google Scholar
• Hoffmann-La RocheA Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated March 3, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01235585?term=NCT01235585&rank=1. NLM identifier: NCT01235585Accessed March 10, 2014
   Google Scholar
• Hoffmann-La RocheA Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated January 20, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01235520?term=NCT01235520&rank=1. NLM identifier: NCT01235520Accessed March 10, 2014
   Google Scholar
• ArangoCNasrallahHLawrieSEfficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics – Results from the Phase III DayLyte studyPoster presented at: 4th Biennial Schizophrenia International Research Society ConferenceApril 5–9, 2014Florence, Italy
   Google Scholar
• BlaettlerTBugarski-KirolaDFleischhackerWEfficacy and safety of adjunctive bitopertin (10 and 20 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics – Results from the Phase III FlashLyte studyPoster presented at: 4th Biennial Schizophrenia International Research Society ConferenceApril 5–9, 2014Florence, Italy
   Google Scholar
• Bugarski-KirolaDArangoCFleischhackerWEfficacy and Safety of Adjunctive Bitopertin versus Placebo in Subjects with Persistent Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics – Update from the SearchLyte ProgrammeSchizophr Res2014153Suppl 1S29
   Google Scholar
• Janssen Research & Development, LLCInvestigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With SchizophreniaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated December 24, 2013]. Available from http://clinicaltrials.gov/show/NCT01323205. NLM identifier: NCT01323205Accessed March 10, 2014
   Google Scholar
• EnVivo Pharmaceuticals, IncStudy of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated February 12, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01714661?term=NCT01714661&rank=1. NLM identifier: NCT01714661Accessed March 10, 2014
   Google Scholar
• EnVivo Pharmaceuticals, IncA 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated February 12, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01714713?term=NCT01714713&rank=1. NLM identifier: NCT01714713Accessed March 10, 2014
   Google Scholar
• Targacept IncEfficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With SchizophreniaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated December 6, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01488929?term=NCT01488929&rank=1. NLM identifier: NCT01488929Accessed March 10, 2014
   Google Scholar
• TargaceptTargacept announces negative top-line results from phase 2b clinical trial of TC-5619 in schizophrenia [press release]12162013 Available from: http://www.targacept.com/newsroom/index.cfmAccessed March 5, 2014
   Google Scholar
• SommerIEvan WestrhenenRBegemannMJde WitteLDLeuchtSKahnRSEfficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An updateSchizophr Bull201440118119124106335
   PubMed Web of Science ®Google Scholar
• BerkMMunibADeanOQualitative methods in early-phase drug trials: broadening the scope of data and methods from and RCT of N-acetylcysteine in schizophreniaJ Clin Psychiatry201172790991320868637
   PubMed Web of Science ®Google Scholar
• DeanOGiorlandoFBerkMN-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of actionJ Psychiatry Neurosci2011362788621118657
   PubMed Web of Science ®Google Scholar